Tiziana Life Sciences PLC Stock London S.E.
Equities
GB00B28XMY25
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
Apr. 23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
Apr. 23 | Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program | MT |
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 60.66M |
---|---|---|---|---|---|
Net income 2021 | -23M | Net income 2022 | -15M | EV / Sales 2021 | - |
Net cash position 2021 | 42.19M | Net cash position 2022 | 17.76M | EV / Sales 2022 | - |
P/E ratio 2021 |
-4.01
x | P/E ratio 2022 |
-3.95
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 32.56% |
Latest transcript on Tiziana Life Sciences PLC
Managers | Title | Age | Since |
---|---|---|---|
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 98-02-10 |
Keeren Shah
DFI | Director of Finance/CFO | 47 | - |
Vaseem Palejwala
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 20-06-30 |
Willy Simon
BRD | Director/Board Member | 72 | 15-10-31 |
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 98-02-10 |
1st Jan change | Capi. | |
---|---|---|
+20.09% | 42.68B | |
-1.80% | 42.4B | |
+45.04% | 40.04B | |
-6.20% | 28.31B | |
+6.58% | 24.94B | |
-21.57% | 18.96B | |
+30.60% | 12.3B | |
-2.64% | 11.95B | |
-3.30% | 11.55B |